Home » Stocks » APLS

Apellis Pharmaceuticals, Inc. (APLS)

Stock Price: $45.68 USD -2.35 (-4.89%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
After-hours: $46.00 +0.32 (0.70%) Jan 22, 7:52 PM
Market Cap 3.46B
Revenue (ttm) 646,000
Net Income (ttm) -536.36M
Shares Out 75.63M
EPS (ttm) -8.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $45.68
Previous Close $48.03
Change ($) -2.35
Change (%) -4.89%
Day's Open 47.51
Day's Range 45.52 - 48.00
Day's Volume 1,068,535
52-Week Range 17.91 - 57.39

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 3 days ago

WALTHAM, Mass., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the...

GlobeNewsWire - 2 weeks ago

WALTHAM, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that it h...

Zacks Investment Research - 3 weeks ago

Apellis' (APLS) lead pipeline candidate, pegcetacoplan, is a promising one and being developed for several indications.

PRNewsWire - 1 month ago

STOCKHOLM and WALTHAM, Mass., Dec. 10, 2020 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) and Apellis Pharmaceuticals Inc. (Nasdaq: APLS) today announced positive top-l...

GlobeNewsWire - 1 month ago

WALTHAM, Mass. and STOCKHOLM, Sweden, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi™ Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) today annou...

GlobeNewsWire - 1 month ago

WALTHAM, Mass., Dec. 04, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the...

GlobeNewsWire - 1 month ago

WALTHAM, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that th...

Zacks Investment Research - 2 months ago

Apellis (APLS) and Sobi dose the first patient in the mid-stage MERIDIAN study, which is investigating pegcetacoplan to address adults with sporadic amyotrophic lateral sclerosis.

PRNewsWire - 2 months ago

STOCKHOLM and WALTHAM, Mass., Nov. 19, 2020 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (SobiTM) (STO:SOBI) and Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the fir...

GlobeNewsWire - 2 months ago

WALTHAM, Mass. and STOCKHOLM, Sweden, Nov. 19, 2020 (GLOBE NEWSWIRE) --  Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) today announced ...

Zacks Investment Research - 2 months ago

The FDA accepts Apeliis' (APLS) NDA for pegcetacoplanand and grants priority review for the treatment of paroxysmal nocturnal hemoglobinuria.

GlobeNewsWire - 2 months ago

WALTHAM, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that th...

GlobeNewsWire - 2 months ago

WALTHAM, Mass., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced finding...

GlobeNewsWire - 2 months ago

WALTHAM, Mass., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that th...

GlobeNewsWire - 2 months ago

WALTHAM, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that ei...

Zacks Investment Research - 2 months ago

Apellis (APLS) reports a wider-than-expected loss in the third quarter of 2020.

GlobeNewsWire - 2 months ago

WALTHAM, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced its thir...

GlobeNewsWire - 2 months ago

WALTHAM, Mass. and STOCKHOLM, Sweden, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) today announced a...

GlobeNewsWire - 3 months ago

WALTHAM, Mass., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced 18-month...

GlobeNewsWire - 3 months ago

WALTHAM, Mass., Oct. 09, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that pos...

GlobeNewsWire - 3 months ago

WALTHAM, Mass., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced that the co...

GlobeNewsWire - 3 months ago

WALTHAM, Mass., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that it ...

GlobeNewsWire - 3 months ago

WALTHAM, Mass., Oct. 03, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced the resu...

GlobeNewsWire - 4 months ago

WALTHAM, Mass., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced tha...

GlobeNewsWire - 4 months ago

WALTHAM, Mass., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that ...

Zacks Investment Research - 4 months ago

Apellis (APLS) submits an NDA to the FDA and an MAA to the European Medicines Agency for pegcetacoplan for the treatment of paroxysmal nocturnal hemoglobinuria.

Zacks Investment Research - 4 months ago

Apellis Pharmaceuticals, Inc. (APLS) reported earnings 30 days ago.

GlobeNewsWire - 5 months ago

WALTHAM, Mass., July 31, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced its...

Seeking Alpha - 6 months ago

Apellis Trial Progress And Other News: The Good, Bad And Ugly Of Biopharma

GlobeNewsWire - 6 months ago

WALTHAM Mass., July 07, 2020 (GLOBE NEWSWIRE) --   Apellis Pharmaceuticals  Inc., (NASDAQ:APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced that it ...

GlobeNewsWire - 6 months ago

WALTHAM, Mass., July 02, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced the compl...

GlobeNewsWire - 7 months ago

WALTHAM, Mass., June 16, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS) a global biopharmaceutical company pioneering targeted C3 therapies, today announced that the...

Market Watch - 7 months ago

Shares of Apellis Pharmaceuticals Inc. APLS, -3.63% gained 5.1% in premarket trading on Friday after it shared details from a late-stage clinical trial evaluating its experimental drug pegceta...

GlobeNewsWire - 7 months ago

WALTHAM, Mass., June 12, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today presented detaile...

GlobeNewsWire - 7 months ago

WALTHAM, Mass., May 29, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced that the c...

GlobeNewsWire - 7 months ago

WALTHAM, Mass., May 28, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced that the...

GlobeNewsWire - 8 months ago

WALTHAM, Mass., May 21, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced plans to...

GlobeNewsWire - 8 months ago

WALTHAM, Mass., May 14, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced that res...

GlobeNewsWire - 8 months ago

WALTHAM, Mass., May 07, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced that the c...

GlobeNewsWire - 8 months ago

WALTHAM, Mass., May 07, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced that it had...

InvestorPlace - 9 months ago

This week I want to take a bullish position in the underperforming pharmaceutical sector with Apellis Pharmaceuticals, Inc. (NASDAQ:APLS).

Zacks Investment Research - 9 months ago

Apellis Pharmaceuticals (APLS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well

The Motley Fool - 11 months ago

The pre-commercial company is looking to take on a $23 billion industry leader. Promising late-stage clinical results suggest it may have a shot.

GlobeNewsWire - 1 year ago

WALTHAM, Mass., Jan. 16, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced that the ...

GlobeNewsWire - 1 year ago

WALTHAM Mass., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced the closing...

Seeking Alpha - 1 year ago

Apellis Pharmaceuticals Phase 3 Success, And Other News: The Good, Bad, And Ugly Of Biopharma

Seeking Alpha - 1 year ago

Apellis Pharmaceuticals: PEGASUS Trial Confirms Pegcetacoplan's Efficacy Over Soliris In PNH Patients

GlobeNewsWire - 1 year ago

WALTHAM, Mass., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced the pricin...

Zacks Investment Research - 1 year ago

Apellis Pharmaceuticals' (APLS) experimental drug pegcetacoplan outperformed Alexion's blockbuster medicine, Soliris, in a phase III head-to-head study. Shares soar.

GlobeNewsWire - 1 year ago

WALTHAM, Mass., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced that it ha...

About APLS

Apellis Pharmaceuticals, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria diseases; and in Phase II clinical trials for the treatment of cold agglutinin disease, C3 glomerulopathy, IgA nephropathy, primary membranous... [Read more...]

Industry
Biotechnology
IPO Date
Nov 9, 2017
CEO
Cedric Francois
Employees
350
Stock Exchange
NASDAQ
Ticker Symbol
APLS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 15 analysts, the average rating for APLS stock is "Buy." The 12-month stock price forecast is 62.64, which is an increase of 37.13% from the latest price.

Price Target
$62.64
(37.13% upside)
Analyst Consensus: Buy